Unknown

Dataset Information

0

High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative colitis.


ABSTRACT: Accurate and high-throughput technologies are needed for identification of new therapeutic targets and for optimizing therapy in inflammatory bowel disease. Our aim was to assess multi-analyte protein-based assays of cytokines/chemokines using Luminex technology. We have reported that Luminex-based profiling was useful in assessing response to L-arginine therapy in the mouse model of dextran sulfate sodium colitis. Therefore, we studied prospectively collected samples from ulcerative colitis (UC) patients and control subjects. Serum, colon biopsies, and clinical information were obtained from subjects undergoing colonoscopy for evaluation of UC or for non-UC indications. In total, 38 normal controls and 137 UC cases completed the study. Histologic disease severity and the Mayo Disease Activity Index (DAI) were assessed. Serum and colonic tissue cytokine/chemokine profiles were measured by Luminex-based multiplex testing of 42 analytes. Only eotaxin-1 and G-CSF were increased in serum of patients with histologically active UC vs. controls. While 13 cytokines/chemokines were increased in active UC vs. controls in tissues, only eotaxin-1 was increased in all levels of active disease in both serum and tissue. In tissues, eotaxin-1 correlated with the DAI and with eosinophil counts. Increased eotaxin-1 levels were confirmed by real-time PCR. Tissue eotaxin-1 levels were also increased in experimental murine colitis induced by dextran sulfate sodium, oxazolone, or Citrobacter rodentium, but not in murine Helicobacter pylori infection. Our data implicate eotaxin-1 as an etiologic factor and therapeutic target in UC, and indicate that Luminex-based assays may be useful to assess IBD pathogenesis and to select patients for anti-cytokine/chemokine therapies.

SUBMITTER: Coburn LA 

PROVIDER: S-EPMC3867379 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications


Accurate and high-throughput technologies are needed for identification of new therapeutic targets and for optimizing therapy in inflammatory bowel disease. Our aim was to assess multi-analyte protein-based assays of cytokines/chemokines using Luminex technology. We have reported that Luminex-based profiling was useful in assessing response to L-arginine therapy in the mouse model of dextran sulfate sodium colitis. Therefore, we studied prospectively collected samples from ulcerative colitis (UC  ...[more]

Similar Datasets

| S-EPMC3524125 | biostudies-literature
| S-EPMC3269563 | biostudies-literature
| S-EPMC3754681 | biostudies-literature
| S-EPMC2728352 | biostudies-literature
| S-EPMC4531309 | biostudies-literature
| S-EPMC9850088 | biostudies-literature
| S-EPMC8672077 | biostudies-literature
2012-09-27 | GSE27899 | GEO
2014-09-05 | E-GEOD-48634 | biostudies-arrayexpress
2014-09-05 | GSE48634 | GEO